{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T20:09:12Z","timestamp":1778357352401,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtct.2025.11.016","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:15:51Z","timestamp":1764173751000},"page":"373.e1-373.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic Findings of Potential Donor Origin in Cells Used for Cell and Gene Therapy: Recommendations from the World Marrow Donor Association"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8420-8340","authenticated-orcid":false,"given":"Angharad","family":"Pryce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1599-1869","authenticated-orcid":false,"given":"Meghann","family":"Cody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer","family":"Madbouly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6174-3967","authenticated-orcid":false,"given":"Eefke","family":"van Eerden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6717-959X","authenticated-orcid":false,"given":"Laura L.","family":"Machin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather E.","family":"Stefanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren","family":"Hatton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5268-2707","authenticated-orcid":false,"given":"Chloe","family":"Anthias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1353-2175","authenticated-orcid":false,"given":"Diana","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5867-3978","authenticated-orcid":false,"given":"Sarah","family":"Bannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-1094","authenticated-orcid":false,"given":"Thilo","family":"Mengling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-8289","authenticated-orcid":false,"given":"David S.","family":"Allan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.11.016_bib0001","unstructured":"European Medicines Agency (EMA). Advanced therapy medicinal products: overview. Available at:https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/advanced-therapy-medicinal-products-overview. Accessed February 20, 2025."},{"key":"10.1016\/j.jtct.2025.11.016_bib0002","unstructured":"United States Food and Drug Administration. Cellular & gene therapy products. Available at:https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products. Accessed February 20, 2025."},{"key":"10.1016\/j.jtct.2025.11.016_bib0003","unstructured":"Alliance for Regenerative Medicine. Available products: a comprehensive list of current cell and gene therapy products available in different markets across the world. Available at: https:\/\/alliancerm.org\/available-products. Accessed February 20, 2025."},{"issue":"5","key":"10.1016\/j.jtct.2025.11.016_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103549","article-title":"A pipeline analysis of advanced therapy medicinal products","volume":"28","author":"Wilkins","year":"2023","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.016_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jtct.2023.11.019","article-title":"Genetic findings of potential donor origin following hematopoietic cell transplantation: recommendations on donor disclosure and genetic testing from the World Marrow Donor Association","volume":"30","author":"Pryce","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.11.016_bib0006","unstructured":"Gov UK. Donation of starting material for advanced cell-based therapies. July 4, 2014. Available at:https:\/\/www.gov.uk\/government\/publications\/donation-of-starting-material-for-advanced-cell-based-therapies. Accessed February 20, 2025."},{"key":"10.1016\/j.jtct.2025.11.016_bib0007","unstructured":"United States Food and Drug Administration. Guidance for Industry Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps). Available at:https:\/\/www.fda.gov\/files\/vaccines,%20blood%20&%20biologics\/published\/Eligibility-Determination-for-Donors-of-Human-Cells--Tissues--and-Cellular-and-Tissue-Based-Products--Guidance-for-Industry.pdf. Accessed January 8, 2026."},{"key":"10.1016\/j.jtct.2025.11.016_bib0008","unstructured":"Internal audit. Increase in cell and gene therapy donor requests, Anthony Nolan, UK."},{"key":"10.1016\/j.jtct.2025.11.016_bib0009","unstructured":"United States Food and Drug Administration. Testing human cells, tissues, and cellular and tissue-based product (HCT\/P) donors for relevant communicable disease agents and diseases.https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/testing-human-cells-tissues-and-cellular-and-tissue-based-product-hctp-donors-relevant-communicable. Accessed January 8, 2026."},{"issue":"7","key":"10.1016\/j.jtct.2025.11.016_bib0010","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/bmt.2014.67","article-title":"Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee","volume":"49","author":"Lown","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.11.016_bib0011","unstructured":"European Medicines Agency (EMA). New guidelines on good manufacturing practices for advanced therapies. November 24, 2017. Available at: https:\/\/www.ema.europa.eu\/en\/news\/new-guidelines-good-manufacturing-practices-advanced-therapies. Accessed June 18, 2025."},{"issue":"3","key":"10.1016\/j.jtct.2025.11.016_bib0012","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.2023023699","article-title":"How I use next-generation sequencing\u2013MRD to plan approach and prevent relapse after HCT for children and adults with ALL","volume":"144","author":"Muffly","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.016_bib0013","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood.2024024870","article-title":"Transplant, MRD, and predicting relapse in AML","volume":"144","author":"Radich","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.11.016_bib0014","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Acute Lymphoblastic Leukemia. Version 3.2024. December 20, 2024. Available at: NCCN.org. Accessed March 4, 2025."},{"key":"10.1016\/j.jtct.2025.11.016_bib0015","unstructured":"eCFR:: 21 CFR 1271.220 \u2013 Processing and process controls."},{"key":"10.1016\/j.jtct.2025.11.016_bib0016","unstructured":"Title 21 Code of Federal Regulations 640.120(a). Exceptions and Alternative Procedures Approved Under 21 CFR 640.120.https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Exceptions-and-Alternative-Procedures\u2014-Approved-Under-21-CFR-640.120.pdf"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.016_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-62544-8","article-title":"Advantages of pooling of human bone marrow-derived mesenchymal stromal cells from different donors versus single donor MSCs","volume":"14","author":"Kannan","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.016_bib0019","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(19)30211-X","article-title":"Assessing clonal heamatopoiesis: clinical burdens and benefits of diagnosis myelodysplastic syndrome precursor states","volume":"7","author":"Gondek","year":"2020","journal-title":"Lancet Harmatol"},{"issue":"8","key":"10.1016\/j.jtct.2025.11.016_bib0031","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/annonc\/mdz136","article-title":"Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO precision medicine working group","volume":"30","author":"Mandelker","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.016_bib0020","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.bbmt.2018.01.033","article-title":"Donor cell-derived hematologic neoplasms after hematopoietic stem cell transplantation: a systematic review","volume":"24","author":"Su\u00e1rez-Gonz\u00e1lez","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.016_bib0021","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.016_bib0022","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1038\/s41467-024-47866-5","article-title":"A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID","volume":"15","author":"Cesana","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2025.11.016_bib0023","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.11.016_bib0024","unstructured":"European Medicines Agency (EMA). Good manufacturing practice. Available at:https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/compliance-research-development\/good-manufacturing-practice. Accessed March 4, 2025."},{"key":"10.1016\/j.jtct.2025.11.016_bib0025","unstructured":"Current good manufacturing practice (CGMP) regulations. Available at:https:\/\/www.fda.gov\/drugs\/pharmaceutical-quality-resources\/current-good-manufacturing-practice-cgmp-regulations. Accessed March 4, 2025."},{"key":"10.1016\/j.jtct.2025.11.016_bib0026","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3389\/fphar.2019.00921","article-title":"Regulatory framework for advanced therapy medicinal products in Europe and the United States","volume":"10","author":"Iglesias-L\u00f3pez","year":"2019","journal-title":"Front Pharm"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.016_bib0027","first-page":"4","article-title":"The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research","volume":"81","year":"2014","journal-title":"J Am Coll Dent"},{"issue":"5","key":"10.1016\/j.jtct.2025.11.016_bib0028","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/jme.2002.001578","article-title":"The right not to know: an autonomy based approach","volume":"30","author":"Andorno","year":"2004","journal-title":"J Med Ethics"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.016_bib0029","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/15265161.2014.880313","article-title":"The \u201cright not to know\u201d in the genomic era: time to break from tradition?","volume":"14","author":"Berkman","year":"2014","journal-title":"Am J Bioeth"},{"key":"10.1016\/j.jtct.2025.11.016_bib0030","unstructured":"Clinical Genome Resource (ClinGen). Available at: https:\/\/clinicalgenome.org. Accessed September 2022."},{"issue":"4","key":"10.1016\/j.jtct.2025.11.016_bib0032","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/bloodadvances.2019000395","article-title":"Stem cell donors should not be screened for clonal haematopoiesis","volume":"4","author":"Gibson","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.11.016_bib0033","unstructured":"NMPD Internal audit (ahead of publication)"},{"key":"10.1016\/j.jtct.2025.11.016_bib0034","unstructured":"Genomics England. 100,000 Genomes Project. Available at:https:\/\/www.genomicsengland.co.uk\/initiatives\/100000-genomes-project\/participant-resources. Accessed March 4, 2025."},{"issue":"6","key":"10.1016\/j.jtct.2025.11.016_bib0035","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41431-019-0570-7","article-title":"Exploring broad consent in the context of the 100,000 Genomes Project: a mixed-methods study","volume":"28","author":"Ballard","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"10.1016\/j.jtct.2025.11.016_bib0036","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.jtct.2025.11.016_bib0037","unstructured":"Ellard S, Baple EL, Callaway A, et al. ACGS best practice guidelines for variant classification in rare disease 2020. The Association for Clinical Genomic Science. Available at:https:\/\/www.acgs.uk.com\/media\/11631\/uk-practice-guidelines-for-variant-classification-v4-01-2020.pdf. Accessed March 4, 2025."},{"issue":"8","key":"10.1016\/j.jtct.2025.11.016_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100866","article-title":"ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Miller","year":"2023","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.jtct.2025.11.016_bib0041","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/jmedgenet-2020-107248","article-title":"Combining evidence for and against pathogenecity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations","volume":"58","author":"Garrett","year":"2021","journal-title":"J Med Genet"},{"key":"10.1016\/j.jtct.2025.11.016_bib0042","unstructured":"British Society for Genetic Medicine. Managing incidental findings. Guidance for rare and inherited disease diagnostic genomic testing. June 2024. Available at: https:\/\/bsgm-managing-incidental-findings-guidance.pdf. Accessed March 4, 2025."},{"key":"10.1016\/j.jtct.2025.11.016_bib0043","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3389\/fgene.2018.00624","article-title":"A systematic review of the psychological implications of genetic testing: a comparative analysis among cardiovascular, neurodegenerative and cancer disease","volume":"9","author":"Oliveri","year":"2018","journal-title":"Front Genet"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672501591X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672501591X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T19:31:47Z","timestamp":1778355107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672501591X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S266663672501591X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.11.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic Findings of Potential Donor Origin in Cells Used for Cell and Gene Therapy: Recommendations from the World Marrow Donor Association","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}